

**The Norwegian Cancer Symposium –
70th Anniversary of the Institute for Cancer Research, Oslo University Hospital**

Programme

Sunday 8 September

20:00 – 22:30 Speakers Dinner

Monday 9 September

9:00 – 9:15 **Opening addresses** (*Chair: Kjetil Taskén*)

9:15 – 9:45 **Keynote address:** Douglas Hanahan, Ludwig Institute for Cancer Research and Swiss Federal Institute of Technology Lausanne (EPFL), Lausanne Switzerland
The Hallmarks of Cancer in 2024

9:45 – 09:50 Q&A

09:50 – 10:15 **Coffee break**

Session 1: The Tumor Microenvironment, Metastasis and Therapy Resistance

Chair: Therese Sørli

10:15 – 10:35 Johanna Ivaska, University of Turku, Finland
Pathways limiting cancer progression.

10:35 – 10:40 Q&A

10:40 – 10:50 Short talk selected from abstracts: José Teles Reis, Institute for Cancer Research, Oslo University Hospital
Dissecting the mutational drivers behind interclonal interactions in Cancer

10:50 – 10:55 Q&A

10:55 – 11:15 Erik Sahai, The Francis Crick Institute, London, UK
Mechanisms of resistance to targeted therapy

11:15 – 11:20 Q&A

11:20 – 11:30 Short talk selected from abstracts: Astrid Medhus, Institute for Cancer Research, Oslo University Hospital
Biomarker guided ADC therapy

11:30 – 11:35 Q&A

11:35 – 11:55 Verena Jendrossek, University Hospital Essen, Germany
Tumor microenvironment, cancer metabolism and radioresistance

11:55 – 12:00 Q&A

12:00 – 13:00 **Poster Session 1, part 1** (Odd-numbered posters)

13:00 – 14:00 **Lunch**

14:00 – 15:00 **Poster Session 1, part 2** (Odd-numbered posters)

15:00 – 15:20 **Coffee break**

Session 2: Risk Stratification, Current and Emerging Treatment Regimens

Chair: Gunhild M. Mælandsmo

15:20 – 15:40 Olli Kallioniemi, Karolinska Institutet & SciLifeLab, Stockholm, Sweden
Data-driven Cancer Hallmarks

15:40 – 15:45 Q&A

15:45 – 15:55 Short talk selected from abstracts: Mev Domingues-Valentin, Institute for Cancer Research, Oslo University Hospital
Towards precision medicine in Lynch Syndrome

15:55 – 16:00 Q&A

16:00 – 16:20 Sibylle Loibl, Goethe-Universität Frankfurt, Germany:
Recent advancement in the treatment of HER2-negative early breast cancer and what biomarkers have taught us

16:20 – 16:25 Q&A

16:25 – 16:35 Short talk selected from abstracts: Mary-Ann Jallad, Institute for Cancer Research, Oslo University Hospital
High-throughput Combination Drug Screening to Overcome Resistance in Breast Cancer

16:35 – 16:40 Q&A

16:40 – 17:00 Manuel R Teixeira, IPO Porto, Portugal
Uncovering the missing heritability of prostate cancer

17:00 – 17:05 Q&A

17:05 – 19:00 **Poster Session 2** (Even-numbered posters)

19:00 **Aperitif Reception Area**

19:30 **Banquet Dinner**

Tuesday 10 September

Session 3: Norwegian Cancer Research

Chair: Eirik Malinen

09:00 – 09:20 Per Eystein Lønning, Haukeland University Hospital and University of Bergen, Norway
Prenatal epimutations and cancer risk; a phenomenon affecting a few, or a major risk factor in certain cancer forms?

09:20 – 09:25 Q&A

09:25 – 09:45 Ragnhild A. Lothe, Institute for Cancer Research, Oslo University Hospital, Norway
70-year History of the Institute for Cancer Research

09:45 – 09:50 Q&A

09:50 – 10:20 **Coffee break**

Session 4: Computational and Functional Precision Cancer Medicine

Chair: Leonardo Meza-Zepeda

10:20 – 10:40 Berend Snijder, ETH Zürich, Switzerland
Probing single-cell biology ex vivo for personalized systems medicine

10:40 – 10:45 Q&A

10:45 – 10:55 Short talk selected from abstracts: Chloe Steen, Institute for Cancer Research, Oslo University Hospital

Pan-cancer Cartography of Human Tumors with CytoSPACE

10:55 – 11:00 Q&A

11:00 – 11:20 *Dentist Olaf Aase and wife memorial lecture:*
Karuna Ganesh, Memorial Sloan Kettering Cancer Centre
Dissecting plasticity during colorectal cancer metastasis

11:20 – 11:25 Q&A

11:30 – 12:30 **Lunch**

12:30 – 12:40 Short talk selected from abstracts: Kushtrim Kryeziu, Institute for Cancer Research, Oslo University Hospital

Patient-derived organoids from metastatic colorectal cancer for functional precision oncology

12:40 – 12:45 Q&A

12:45 – 13:05 Anita Sveen, Institute for Cancer Research, Oslo University Hospital, Norway
Tumor heterogeneity of treatment response and progression of colorectal cancer

13:05 – 13:10 Q&A

Session 5: Cancer Immunology and Immunotherapy

Chair: Harald Stenmark

13:10 – 13:30 Gillian Griffiths, University of Cambridge, UK
Mechanisms of Cytotoxic T-Lymphocyte killing

13:30 – 13:35 Q&A

13:35 – 13:45 Short talk selected from abstracts: Inga Hansine Rye, Institute for Cancer Research, Oslo University Hospital

Tumor size is key driver of local immunological changes in breast cancer

13:45 – 13:50 Q&A

13:50 – 14:20 **Coffee break**

14:20 – 14:40 Reuven Agami, The Netherlands Cancer Institute

Amino acid substitutants, cancer development, and anti-tumor immunity

14:40 – 14:45 Q&A

14:45 – 14:55 Short talk selected from abstracts: Edina Szabo, Institute for Cancer Research, Oslo University Hospital

TIGIT modulates the mitochondrial-metabolism axis and preserves fitness in circulating effector memory T cells

14:55 – 15:00 Q&A

15:00 – 15:20 Johanna Olweus, Institute for Cancer Research, Oslo University Hospital, Norway

Opportunities for therapeutic T-cell receptors in cancer immunotherapy

15:20 – 15:25 Q&A

15:25 – 15:30 Closing words